Anaptysbio, Inc (ANAB): R&D Expense
$135.97M
Year ended 2025-12-31
$128.78M
Trailing 12 months to 2026-03-31
+15.3%
3-year compound annual growth
+11.2%
5-year compound annual growth
+22.9%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $135.97M | -17.0% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $163.84M | +23.9% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $132.28M | +49.0% | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | $88.80M | -9.8% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $98.50M | +23.1% | 2024-03-11, From 2021-01-01 |
| 2020-12-31 | $80.03M | -19.4% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $99.34M | +76.8% | 2022-03-07, From 2019-01-01 |
| 2018-12-31 | $56.20M | +90.9% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $29.44M | +91.0% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $15.42M | -10.9% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $17.30M | n/a | 2018-03-05, From 2015-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $135.97M | -17.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $62.36M | +65.6% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $62.07M | +13.0% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $129.64M | -25.3% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $523.00M | +16.7% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $314.70M | +6.8% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $109.27M | +46.8% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $173.14M | -14.2% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $19.81M | -5.1% |
Compare ANAB, AKBA, PBYI, KROS side by side · Screen every company in Pharmaceutical Preparations ↗